{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:58:04Z","timestamp":1762999084738},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/jhh.2015.24","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T09:19:36Z","timestamp":1427966376000},"page":"35-39","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension"],"prefix":"10.1038","volume":"30","author":[{"given":"O","family":"Petr\u00e1k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Zelinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"\u0160trauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"\u0160oml\u00f3ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Indra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Turkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Holaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"J","family":"Widimsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"issue":"11","key":"BFjhh201524_CR1","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1097\/HJH.0b013e32833d4451","volume":"28","author":"R C\u00edfkov\u00e1","year":"2010","unstructured":"C\u00edfkov\u00e1 R, \u0160kodov\u00e1 Z, Bruthans J, Holub J, Ad\u00e1mkov\u00e1 V, Joz\u00edfov\u00e1 M et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007\/2008. J Hypertens 2010; 28 (11): 2196\u20132203.","journal-title":"J Hypertens"},{"key":"BFjhh201524_CR2","unstructured":"Nwankwo T, Yoon SS, Burt V, Gu Q . Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. Centers for Disease Control and Prevention: Hyattsville, MD, USA, Number 133, October 2013; pp 1\u20138."},{"issue":"8","key":"BFjhh201524_CR3","doi-asserted-by":"publisher","first-page":"e003423","DOI":"10.1136\/bmjopen-2013-003423","volume":"3","author":"M Joffres","year":"2013","unstructured":"Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open 2013; 3 (8): e003423.","journal-title":"BMJ Open"},{"issue":"5","key":"BFjhh201524_CR4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/HJR.0b013e3283383f30","volume":"17","author":"K Kotseva","year":"2010","unstructured":"Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17 (5): 530\u2013540.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"7","key":"BFjhh201524_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281\u20131357.","journal-title":"J Hypertens"},{"issue":"6","key":"BFjhh201524_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403\u20131419.","journal-title":"Hypertension"},{"issue":"6","key":"BFjhh201524_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.111.180497","volume":"58","author":"MR Hanselin","year":"2011","unstructured":"Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV . Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58 (6): 1008\u20131013.","journal-title":"Hypertension"},{"issue":"6","key":"BFjhh201524_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD . Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57 (6): 1076\u20131080.","journal-title":"Hypertension"},{"issue":"11","key":"BFjhh201524_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/jhh.2014.3","volume":"28","author":"J Rosa","year":"2014","unstructured":"Rosa J, Zelinka T, Petr\u00e1k O, \u0160trauch B, \u0160oml\u00f3ov\u00e1 Z, Indra T et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically? J Hum Hypertens 2014; 28 (11): 684\u2013688.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"BFjhh201524_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","volume":"17","author":"B \u0160trauch","year":"2003","unstructured":"\u0160trauch B, Zelinka T, Hampf M, Bernhardt R, Widimsk\u00fd J Jr . Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349\u2013352.","journal-title":"J Hum Hypertens"},{"issue":"9","key":"BFjhh201524_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, C\u00edfkov\u00e1 R, Fagard R, Germano G et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25 (9): 1751\u20131762.","journal-title":"J Hypertens"},{"issue":"22","key":"BFjhh201524_CR12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra0907219","volume":"361","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Moser M . Use of diuretics in patients with hypertension. N Engl J Med 2009; 361 (22): 2153\u20132164.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFjhh201524_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/00003088-199630030-00004","volume":"30","author":"DA Sica","year":"1996","unstructured":"Sica DA, Gehr TW . Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30 (3): 229\u2013249.","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"BFjhh201524_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","volume":"56","author":"JC Jentzer","year":"2010","unstructured":"Jentzer JC, DeWald TA, Hernandez AF . Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56 (19): 1527\u20131534.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"BFjhh201524_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","volume":"30","author":"G Bobrie","year":"2012","unstructured":"Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656\u20131664.","journal-title":"J Hypertens"},{"issue":"1","key":"BFjhh201524_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F de Souza","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G . Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55 (1): 147\u2013152.","journal-title":"Hypertension"},{"issue":"6","key":"BFjhh201524_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J V\u00e1clav\u00edk","year":"2011","unstructured":"V\u00e1clav\u00edk J, Sedl\u00e1k R, Plach\u00fd M, Navratil K, Pl\u00e1\u0161ek J, Jarkovsk\u00fd J et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57 (6): 1069\u20131075.","journal-title":"Hypertension"},{"issue":"4","key":"BFjhh201524_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49 (4): 839\u2013845.","journal-title":"Hypertension"},{"issue":"1","key":"BFjhh201524_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.107.737957","volume":"118","author":"N Chapman","year":"2008","unstructured":"Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR . Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118 (1): 42\u201348.","journal-title":"Circulation"},{"issue":"3","key":"BFjhh201524_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1524-6175.2006.04811.x","volume":"8","author":"HR Black","year":"2006","unstructured":"Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A . Controlled-release doxazosin as combination therapy in hypertension: the GATES study. J Clin Hypertens 2006; 8 (3): 159\u2013166 quiz 167-8.","journal-title":"J Clin Hypertens"},{"key":"BFjhh201524_CR21","doi-asserted-by":"crossref","unstructured":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283 (15): 1967\u20131975.","DOI":"10.1001\/jama.283.15.1967"},{"issue":"9638","key":"BFjhh201524_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372 (9638): 547\u2013553.","journal-title":"Lancet"},{"issue":"11","key":"BFjhh201524_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121\u20132158.","journal-title":"J Hypertens"},{"issue":"23","key":"BFjhh201524_CR24","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367 (23): 2204\u20132213.","journal-title":"N Engl J Med"},{"issue":"12","key":"BFjhh201524_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/hr.2013.86","volume":"36","author":"E Imai","year":"2013","unstructured":"Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S et al. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res 2013; 36 (12): 1051\u20131059.","journal-title":"Hypertens Res"},{"issue":"20","key":"BFjhh201524_CR26","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369 (20): 1892\u20131903.","journal-title":"N Engl J Med"},{"issue":"3","key":"BFjhh201524_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","volume":"52","author":"L Tylicki","year":"2008","unstructured":"Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52 (3): 486\u2013493.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"BFjhh201524_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31 (1): 59\u201367.","journal-title":"Hypertens Res"},{"issue":"11","key":"BFjhh201524_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","volume":"28","author":"B Alvarez-Alvarez","year":"2010","unstructured":"Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N . Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28 (11): 2329\u20132335.","journal-title":"J Hypertens"},{"issue":"7","key":"BFjhh201524_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12325-010-0039-0","volume":"27","author":"J Buch","year":"2010","unstructured":"Buch J . Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther 2010; 27 (7): 426\u2013443.","journal-title":"Adv Ther"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201524","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:05:37Z","timestamp":1647525937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFjhh201524"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2015.24","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]},"assertion":[{"value":"19 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}